AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3003315 — intervention group
Group type: COMPARATOR
Intervention: Blood products from random donors
Number of subjects: 35
Study 3003315 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired CMV infection
Number of subjects: 35
Study 31398987 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol/ascorbic acid (PEGA) in split-dose regimen
Number of subjects: 558
Study 31398987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate formula (SIR) in split-dose regimen
Number of subjects: 558
Study 31398987 — intervention group
Group type: COMPARATOR
Intervention: Sodium picosulfate/magnesium citrate (SPMC)
Number of subjects: 558
Study 30307370 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint‐induced movement therapy and bimanual therapy
Number of subjects: 22
Study 30307370 — intervention group
Group type: COMPARATOR
Intervention: Middle cerebral artery infarct group
Number of subjects: 22
Study 26358288 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.6 mg E
Number of subjects: 415
Study 26358288 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label Liraglutide (1.2 or 1.8 mg)
Number of subjects: 415
Study 26358288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 24341659 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (100 mg)
Number of subjects: 40
Study 24341659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21515055 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar reshaping
Number of subjects: 133
Study 21515055 — intervention group
Group type: COMPARATOR
Intervention: Patellar resurfacing
Number of subjects: 133
Study 20572210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-ED websites
Number of subjects: 100
Study 20572210 — intervention group
Group type: COMPARATOR
Intervention: Healthy/exercise websites
Number of subjects: 100
Study 20572210 — intervention group
Group type: COMPARATOR
Intervention: Tourist websites
Number of subjects: 100
Study 17646235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary radioaerosol mucociliary clearance (PRMC) test
Number of subjects: 95
Study 17032285 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole
Number of subjects: 20
Study 17032285 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rabeprazole
Number of subjects: 20
Study 17032285 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 20
Study 12702905 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment (group A) - prolonged IFN therapy to maintain negative serum HBV-DNA levels for 6 months
Number of subjects: 65
Study 12702905 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (group B) - treated for only 6 months
Number of subjects: 65
Study 12702905 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment (group A)
Number of subjects: 65
Study 12702905 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (group B)
Number of subjects: 65
Study 10714565 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and didanosine
Number of subjects: 55
Study 10714565 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine/didanosine/nevirapine
Number of subjects: 55
Study 10714565 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant combination 601 + 215Y/F
Number of subjects: 55
Study 10714565 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid identity at position 215
Number of subjects: 55
Study 10714565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations 215 + 44 and 41 + 202
Number of subjects: 55
Study 9370846 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.03 mg.kg-1
Number of subjects: 48
Study 9370846 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 48
Study 8286254 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototesting device with metal foil apertures (1, 2, 4, 8 J/cm2)
Number of subjects: 11
Study 8286254 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototesting device
Number of subjects: 11
Study 8286254 — intervention group
Group type: COMPARATOR
Intervention: Control device with four open apertures
Number of subjects: 11
Study 3514473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (OFX) 2 X 200 mg/day (n = 21)
Number of subjects: 41
Study 3514473 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (D) 2 X 100 mg/day (n = 20)
Number of subjects: 41
Study 30200935 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (delivered 2-3 times weekly with educational, motivational, and supportive content)
Number of subjects: 0
Study 30200935 — intervention group
Group type: COMPARATOR
Intervention: Standard care (monitoring only)
Number of subjects: 0
Study 26994063 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal analyses of observational data
Number of subjects: 0
Study 26994063 — intervention group
Group type: EXPERIMENTAL
Intervention: Framework for comparative effectiveness research using big data
Number of subjects: 0
Study 24984178 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP4F2 GA/AA genotype
Number of subjects: 53
Study 24984178 — intervention group
Group type: COMPARATOR
Intervention: CYP4F2 GG (wildtype)
Number of subjects: 53
Study 22642962 — intervention group
Group type: EXPERIMENTAL
Intervention: Low demanding/high responsive feeding style
Number of subjects: 383
Study 22642962 — intervention group
Group type: COMPARATOR
Intervention: High demanding/high responsive feeding style
Number of subjects: 383
Study 20227347 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 19257
Study 20227347 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 19257
Study 20227347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19257
Study 20227347 — intervention group
Group type: COMPARATOR
Intervention: Diuretic
Number of subjects: 19257
Study 18432382 — intervention group
Group type: EXPERIMENTAL
Intervention: Family drinking and perceived drinking norms
Number of subjects: 1318
Study 18432382 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived benefits of drinking
Number of subjects: 1318
Study 15757960 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening by abdominal ultrasonography
Number of subjects: 12639
Study 15757960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 12639
Study 12860868 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose lexipafant (10 mg)
Number of subjects: 150
Study 12860868 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose lexipafant (100 mg)
Number of subjects: 150
Study 12860868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 10100181 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/day for 21 days + chlormadinone acetate for 5 days
Number of subjects: 50
Study 10100181 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 1.25 mg/day for 21 days + chlormadinone acetate for 5 days
Number of subjects: 50
Study 10100181 — intervention group
Group type: COMPARATOR
Intervention: Control group of regularly menstruating women
Number of subjects: 50
Study 8926014 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.10 micrograms/kg/min)
Number of subjects: 19
Study 8926014 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.15 micrograms/kg/min)
Number of subjects: 19
Study 8926014 — intervention group
Group type: COMPARATOR
Intervention: NaCl (control)
Number of subjects: 19
Study 1905495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (800 IU/day) for 48 days
Number of subjects: 21
Study 1905495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1905495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (800 IU/day)
Number of subjects: 21
Study 6410292 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 139
Study 6410292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 31530174 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) during NH
Number of subjects: 13
Study 31530174 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) during HH
Number of subjects: 13
Study 31530174 — intervention group
Group type: COMPARATOR
Intervention: No PEP during HH
Number of subjects: 13
Study 31530174 — intervention group
Group type: COMPARATOR
Intervention: No PEP during NN
Number of subjects: 13
Study 31530174 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP in all sessions
Number of subjects: 13
Study 29166720 — intervention group
Group type: EXPERIMENTAL
Intervention: Firehawk stent
Number of subjects: 460
Study 29166720 — intervention group
Group type: COMPARATOR
Intervention: Xience V stent
Number of subjects: 460
Study 26024851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2910
Study 26024851 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2910
Study 26024851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2910
Study 23059701 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy plus usual care
Number of subjects: 105
Study 23059701 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study 22036946 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person (IP) intervention
Number of subjects: 0
Study 22036946 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based (IB) intervention
Number of subjects: 0
Study 17895912 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate vitamins (vitamin C (300 mg) and E (75 IU) and folic acid (1 mg))
Number of subjects: 30
Study 17895912 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of vitamins (vitamin C (2 g) and E (800 IU), and folic acid (5 mg))
Number of subjects: 30
Study 17895912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream (high-fat challenge)
Number of subjects: 30
Study 17895912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15996669 — intervention group
Group type: EXPERIMENTAL
Intervention: Lullaby music during kangaroo care for 60 min/section/day for three consecutive days
Number of subjects: 30
Study 15996669 — intervention group
Group type: COMPARATOR
Intervention: Routine incubator care
Number of subjects: 30
Study 15200636 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer game that pairs self-relevant information with smiling faces
Number of subjects: 0
Study 11136518 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day of pentavalent antimony (Sb5+) for 30 to 45 days
Number of subjects: 36
Study 11136518 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day of pentavalent antimony (Sb5+)
Number of subjects: 36
Study 11136518 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent use of larger doses of antimony
Number of subjects: 36
Study 9324146 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhiatal (TH) resection
Number of subjects: 39
Study 9324146 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic (TT) resection
Number of subjects: 39
Study 8406345 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 IU of growth hormone/m2/week
Number of subjects: 25
Study 8406345 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 IU of growth hormone/m2/week
Number of subjects: 25
Study 8406345 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 25
Study 2936772 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1 gm/day for 4 weeks, then 333 mg/day for 8 weeks)
Number of subjects: 200
Study 2936772 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (1 gm/day for 4 weeks, then 500 mg/day for 8 weeks)
Number of subjects: 200
Study 2936772 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 200
Study 2936772 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 200
Study 29126661 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day coupon at checkout for half-off eligible fresh, frozen, or canned fruits and vegetables over 4 months
Number of subjects: 401
Study 28963304 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) HIV VL monitoring and potential task shifting to enrolled nurses
Number of subjects: 396
Study 28963304 — intervention group
Group type: COMPARATOR
Intervention: Laboratory VL monitoring and standard South African HIV care
Number of subjects: 396
Study 25761367 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS)
Number of subjects: 35
Study 25761367 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 35
Study 23210764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuned waveform (3.5 milliseconds membrane time constant)
Number of subjects: 52
Study 23210764 — intervention group
Group type: COMPARATOR
Intervention: 50/50% tilt waveform
Number of subjects: 52
Study 21843110 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate switch to levodopa/carbidopa/entacapone (LCE)
Number of subjects: 350
Study 21843110 — intervention group
Group type: COMPARATOR
Intervention: Delayed switch to levodopa/carbidopa/entacapone (LCE)
Number of subjects: 350
Study 18587236 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg i.v. 5‐MTHF
Number of subjects: 341
Study 18587236 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/day oral folic acid
Number of subjects: 341
Study 16466331 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire (intervention group)
Number of subjects: 194
Study 16466331 — intervention group
Group type: COMPARATOR
Intervention: Usual methods of referral (control group)
Number of subjects: 194
Study 12644413 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine premedication
Number of subjects: 0
Study 12644413 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam (control)
Number of subjects: 0
Study 11813275 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE) translated to Sinhalese
Number of subjects: 380
Study 11813275 — intervention group
Group type: COMPARATOR
Intervention: Cognitively normal subjects (scored >17 on MMSE)
Number of subjects: 380
Study 9732167 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Number of subjects: 47
Study 9732167 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 500 mg
Number of subjects: 47
Study 9732167 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg
Number of subjects: 47
Study 9732167 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall relapse rate
Number of subjects: 47
Study 9732167 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse rates over time
Number of subjects: 47
Study 9732167 — intervention group
Group type: COMPARATOR
Intervention: Comparison of relapse rates
Number of subjects: 47
Study 8027279 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone (FSH) 225 IU/day for 5 days
Number of subjects: 10
Study 8027279 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 2 ml/day for 5 days
Number of subjects: 10
Study 2524571 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine dihydrochloride lozenges (5 mg, sucked three times daily after meals for 2 weeks)
Number of subjects: 21
Study 2524571 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges (all ingredients except chlorhex HCl)
Number of subjects: 21
Study 29044395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol lowering (mean reduction of about 1.0 mmol/L) in men with average cholesterol and no CHD
Number of subjects: 6595
Study 29044395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol lowering in men with a history of CHD
Number of subjects: 6595
Study 29044395 — intervention group
Group type: COMPARATOR
Intervention: Lowest cholesterol group (mean 4.0 mmol/L)
Number of subjects: 6595
Study 29044395 — intervention group
Group type: COMPARATOR
Intervention: Highest cholesterol group (mean 8.8 mmol/L)
Number of subjects: 6595
Study 25816315 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled UMEC/VI 62.5/25 μg (delivering 55/22 μg)
Number of subjects: 20
Study 25816315 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled UMEC/VI 125/25 μg (delivering 113/22 μg)
Number of subjects: 20
Study 25816315 — intervention group
Group type: COMPARATOR
Intervention: UMEC 62.5 μg (monotherapy)
Number of subjects: 20
Study 25816315 — intervention group
Group type: COMPARATOR
Intervention: UMEC 125 μg (monotherapy)
Number of subjects: 20
Study 25816315 — intervention group
Group type: COMPARATOR
Intervention: VI 25 μg (monotherapy)
Number of subjects: 20
Study 24074303 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri NCIMB 30242
Number of subjects: 127
Study 24074303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 21840164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) + Venlafaxine XR
Number of subjects: 117
Study 21840164 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR alone
Number of subjects: 117
Study 18954956 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive information
Number of subjects: 100
Study 18954956 — intervention group
Group type: COMPARATOR
Intervention: Minimal information
Number of subjects: 100
Study 17908740 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visits
Number of subjects: 743
Study 17908740 — intervention group
Group type: COMPARATOR
Intervention: Comparison services
Number of subjects: 743
Study 15147075 — intervention group
Group type: EXPERIMENTAL
Intervention: STRESSEN for 30 days
Number of subjects: 40
Study 15147075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific therapy)
Number of subjects: 40
Study 11569760 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of cognitive resources through time pressure
Number of subjects: 0
Study 11569760 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of cognitive resources through a concurrent tone task
Number of subjects: 0
Study 11569760 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 9768527 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 0.25 mg b.d.
Number of subjects: 25
Study 9768527 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 4 mg b.d.
Number of subjects: 25
Study 9768527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7921222 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropins (1000-2500 IE hCG twice per week and 75-150 IE hMG three times per week)
Number of subjects: 26
Study 7921222 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) (5-20 micrograms every 120 min)
Number of subjects: 26
Study 7921222 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropins or GnRH
Number of subjects: 26
Study 31970675 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Liujunzi Decoction (MLJZT)
Number of subjects: 156
Study 31970675 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-based chemotherapy alone (Control group)
Number of subjects: 156
Study 29937256 — intervention group
Group type: COMPARATOR
Intervention: Training workshop plus enhanced consultation (C+)
Number of subjects: 14
Study 29937256 — intervention group
Group type: COMPARATOR
Intervention: Training workshop with basic consultation (C)
Number of subjects: 14
Study 27188910 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (n=30)
Number of subjects: 60
Study 27188910 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (n=30)
Number of subjects: 60
Study 24366401 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care
Number of subjects: 1181
Study 24366401 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy‐informed education
Number of subjects: 1181
Study 24366401 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus nurse support
Number of subjects: 1181
Study 24366401 — intervention group
Group type: COMPARATOR
Intervention: Literacy‐informed education with nurse support
Number of subjects: 1181
Study 21831489 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey dressings
Number of subjects: 70
Study 21831489 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressings (control)
Number of subjects: 70
Study 20488885 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 2 x 500 mg + MTX
Number of subjects: 512
Study 20488885 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 2 x 1000 mg + MTX
Number of subjects: 512
Study 20488885 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 512
Study 18773726 — intervention group
Group type: EXPERIMENTAL
Intervention: In-car noise at real-world level
Number of subjects: 7
Study 18773726 — intervention group
Group type: COMPARATOR
Intervention: Reduced in-car noise by 5 dB
Number of subjects: 7
Study 16166411 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute treatment for late-life depression with Cluster C PDs
Number of subjects: 0
Study 16166411 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation or maintenance treatment for late-life depression with Cluster C PDs
Number of subjects: 0
Study 16166411 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment for late-life depression with Cluster C PDs and residual depressive symptoms
Number of subjects: 0
Study 12963902 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 0.4 mg/kg/d for 1 year
Number of subjects: 26
Study 12963902 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 0.4 mg/kg/d for 3 months followed by 0.2 mg/kg/d for 9 months
Number of subjects: 26
Study 10548673 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced use therapy (immobilization of the unaffected arm combined with intensive training)
Number of subjects: 66
Study 10548673 — intervention group
Group type: COMPARATOR
Intervention: Bimanual training (reference therapy based on Neuro‐Developmental Treatment)
Number of subjects: 66
Study 10548673 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced use therapy
Number of subjects: 66
Study 8724933 — intervention group
Group type: EXPERIMENTAL
Intervention: learner‐guided instructions
Number of subjects: 90